Prostate Cancer Nuclear Medicine Diagnostics Market Scope And Analysis

Report Code : TIPRE00009519
Category : Life Sciences

Status : Published
No. of Pages : 180

Buy Now

Prostate Cancer Nuclear Medicine Diagnostics Market Scope and Analysis Report by 2028

Buy Now

Prostate Cancer Nuclear Medicine Diagnostics Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 720.12 Million
Market Size by 2028	US$ 1,315.66 Million
Global CAGR (2022 - 2028)	10.6%
Historical Data	2020-2021
Forecast period	2023-2028
Segments Covered	By Type PET and SPECT By PET Product F-18 C-11 Ga68-PSMA By End User Hospitals Clinics
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Blue Earth Diagnostics Limited ImaginAB Curium Jubilant Radiopharma NCM USA LLC ABX Advanced Biochemical Compounds GmbH Telix Pharmaceuticals Ltd Novartis AG Theragonostics

Prostate Cancer Nuclear Medicine Diagnostics– Market Segmentation

The global prostate cancer nuclear medicine diagnostics market is analyzed on the basis of type, PET product, end user, and geography. In terms of type, the market is bifurcated into PET and SPECT. Based on PET product, the market is segmented into F-18, C-11, and Ga68-PSMA. Based on end user, the market is segmented into hospitals, clinics, and others. Geographically, the prostate cancer nuclear medicine diagnostics market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.

Company Profiles

Blue Earth Diagnostics Limited
ImaginAb
Curium
Jubilant Radiopharma
NCM-USA LLC
ABX advanced biochemical compounds GmbH
Telix Pharmaceuticals Ltd.
Novartis AG
Theragnostics
Lantheus Medical Imaging, Inc.